Literature DB >> 16156943

Some current issues in breast cancer screening.

Stephen W Duffy1.   

Abstract

Randomized trials of mammography have demonstrated the efficacy of mammographic screening for breast cancer in terms of preventing deaths, but various issues of particular interest remain, including: quantification of overdiagnosis; evaluation of service screening outside the research setting; absolute benefit in terms of number needed to screen per life saved; which types of tumours benefit most from early detection; use of screening data to investigate tumour biology and natural history. This paper describes examples of approaches to the above issues, along with some important results.

Entities:  

Mesh:

Year:  2005        PMID: 16156943     DOI: 10.1258/0969141054855319

Source DB:  PubMed          Journal:  J Med Screen        ISSN: 0969-1413            Impact factor:   2.136


  7 in total

1.  Rate of over-diagnosis of breast cancer 15 years after end of Malmö mammographic screening trial: follow-up study.

Authors:  Sophia Zackrisson; Ingvar Andersson; Lars Janzon; Jonas Manjer; Jens Peter Garne
Journal:  BMJ       Date:  2006-03-03

2.  Over-diagnosis in breast cancer screening.

Authors:  Henrik Møller; Elizabeth Davies
Journal:  BMJ       Date:  2006-03-03

3.  Absolute numbers of lives saved and overdiagnosis in breast cancer screening, from a randomized trial and from the Breast Screening Programme in England.

Authors:  Stephen W Duffy; Laszlo Tabar; Anne Helene Olsen; Bedrich Vitak; Prue C Allgood; Tony H H Chen; Amy M F Yen; Robert A Smith
Journal:  J Med Screen       Date:  2010       Impact factor: 2.136

4.  Overdiagnosis among women attending a population-based mammography screening program.

Authors:  Ragnhild Sørum Falk; Solveig Hofvind; Per Skaane; Tor Haldorsen
Journal:  Int J Cancer       Date:  2013-02-25       Impact factor: 7.396

5.  What is the point: will screening mammography save my life?

Authors:  John D Keen; James E Keen
Journal:  BMC Med Inform Decis Mak       Date:  2009-04-02       Impact factor: 2.796

6.  Reduction in interval cancer rates following the introduction of two-view mammography in the UK breast screening programme.

Authors:  A Dibden; J Offman; D Parmar; J Jenkins; J Slater; K Binysh; J McSorley; S Scorfield; P Cumming; X-H Liao; M Ryan; D Harker; G Stevens; N Rogers; R Blanks; S Sellars; J Patnick; S W Duffy
Journal:  Br J Cancer       Date:  2013-12-24       Impact factor: 7.640

7.  Fibronectin affects transient MMP2 gene expression through DNA demethylation changes in non-invasive breast cancer cell lines.

Authors:  Isabela T Pereira; Edneia A S Ramos; Erico T Costa; Anamaria A Camargo; Graciele C M Manica; Liliane M B Klassen; Andressa Chequin; Karin Braun-Prado; Fábio de O Pedrosa; Emanuel M Souza; Fabricio F Costa; Giseli Klassen
Journal:  PLoS One       Date:  2014-09-10       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.